Drug Development

This study used biological indicators containing Geobacillus stearothermophilus spores and a new technology to continuously monitor incubated BIs and record nonsterile results.

Team leaders in FDA's Office of Generic Drugs provide an overview.

Plus, novel dosage forms and emerging trends.

From healthcare to corruption to life expectancy, here's what we can learn from the past decade.

Directors and staff miss the mark when it comes to following procedures.

Tumour-penetrating microparticles (TPM), drug delivery vehicles that have been designed to specifically target and infiltrate peritoneal tumours, are more efficacious than standard chemotherapy, according to our preliminary research data.

BioNanomatrix (Philadelphia) names Edward Erickson president and CEO; and More.

Merck & Co. Acquires Avecia Biologics; Ambrilia Biopharma Closes Manufacturing Facility; And More.

Also, Abbott to acquire Starlims Technologies; GSK Biologicals to form alliance with Intercell.

Company and People Notes: Also, Pfizer and Protalix enter agreement; Watson acquires Arrow Group; and more.

Also, Merck & Co. extends collaboration with Idera Pharmaceuticals; Pfizer establishes R&D center in China; more...

Readers can learn about the importance of measuring and controlling water activity in a comprehensive new book.

Particularly in a more connected world, individual contributions can make a difference.

Dumbed-down presentations and poor speaker selections are destroying a valuable industry tool.

With so many healthcare and pharmacy websites, consumers could use the agency's nod of support.

Leading experts share insight on polymorphism and crystallization.

Polymorph screening is a critical step in developing an active pharmaceutical ingredient for a pharmaceutical formulation.

The authors discuss a study that demonstrates the use of polyethylene oxide mixtures to investigate the effect of polymer viscosity on formulation robustness.

Blame it on cafeteria gossip, outdated procedures, and major miscommunication.

Company and People Notes: Merck KGaA to build R&D hub in Beijing; Depomed appoints VP of operations; more...

Around half of all multiple sclerosis (MS) patients that are eligible for treatment do not receive it and one in five of those patients that do begin therapy, delay doing so because of fear and anxiety over the treatment process, and not fear and anxiety about the disease.

Company and People Notes: Genzyme provides updates on enzyme replacement products and FDA complete response letter; Watson appoints VP of global operations; more...

Recent advances in microreactor technology are improving the application and scale at which the technology can be applied.

Company and People Notes: 3M forms agreement with VaxInnate; TRIN Pharma appoints CEO; More...

In response to a request from the FDA, the US Pharmacopeial Convention (USP) has revised its standards for propylene glycol and sorbitol solution, excipients widely used in prescription and over-the-counter drugs.